Preclinical and Clinical Studies of Novel Breast Cancer Drugs Targeting Molecules Involved in Protein Kinase C Signaling, the Putative Metastasis-Suppressor Gene Cap43 and the Y-box Binding Protein-1

Publisher： Bentham Science Publishers

E-ISSN： 1875-533x|15|6|528-537

ISSN： 0929-8673

Source： Current Medicinal Chemistry, Vol.15, Iss.6, 2008-03, pp. : 528-537

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Protein kinase C inhibitors as novel anticancer drugs

By Jirousek Michael R   Goekjian Peter G  

Expert Opinion on Investigational Drugs, Vol. 10, Iss. 12, 2001-12 ,pp. : 2117-2140

Informa Healthcare

Access to resources Recommend Favorite

The Pros and Cons of Targeting Protein Kinase c (PKC) in the Management of Cancer Patients

By  

Current Pharmaceutical Biotechnology, Vol. 12, Iss. 11, 2011-11 ,pp. : 1961-1973

Bentham Science Publishers

Access to resources Recommend Favorite

Targeting Protein Kinase C (PKC) in Physiology and Cancer of the Gastric Cell System

By  

Current Medicinal Chemistry, Vol. 15, Iss. 12, 2008-05 ,pp. : 1175-1191

Bentham Science Publishers

Access to resources Recommend Favorite

Disulfiram, and Disulfiram Derivatives as Novel Potential Anticancer Drugs Targeting the Ubiquitin Proteasome System in Both Preclinical and Clinical Studies

By  

Current Cancer Drug Targets, Vol. 11, Iss. 3, 2011-03 ,pp. : 338-346

Bentham Science Publishers

Access to resources Recommend Favorite

Protein Kinase C Isozymes, Novel Phorbol Ester Receptors and Cancer Chemotherapy

By  

Current Pharmaceutical Design, Vol. 7, Iss. 17, 2001-11 ,pp. : 1725-1744

Bentham Science Publishers

Access to resources Recommend Favorite